



Resource impact statement

Resource impact

Published: 18 August 2021

www.nice.org.uk

No significant resource impact is anticipated

NICE has recommended chlormethine gel as an option for treating early stage (stage 1A, 1B and 2A) mycosis fungoides-type cutaneous T-cell lymphoma in adults.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the technology is a further treatment option and the overall cost of treatment will be similar.

Chlormethine gel has a discount that is commercial in confidence. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

This technology is commissioned by NHS England and Improvement. Providers are NHS hospital trusts.